ClinicalTrials.gov record
Terminated Phase 2 Interventional

Capecitabine, Oxaliplatin and Trastuzumab in Treating Patients With HER2 Positive Metastatic Breast Cancer

ClinicalTrials.gov ID: NCT00216073

Public ClinicalTrials.gov record NCT00216073. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 29, 2026, 12:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II Trial of Capecitabine, Oxaliplatin and Trastuzumab (CAPOX-T) in Patients With HER-2 Positive Metastatic Breast Cancer: Hoosier Oncology Group BRE03-61

Study identification

NCT ID
NCT00216073
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Hoosier Cancer Research Network
Other
Enrollment
11 participants

Conditions and interventions

Interventions

  • Capecitabine Drug
  • Oxaliplatin Drug
  • Trastuzumab Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 29, 2004
Primary completion
Sep 30, 2006
Completion
Sep 30, 2006
Last update posted
May 1, 2011

2004 – 2006

United States locations

U.S. sites
11
U.S. states
3
U.S. cities
9
Facility City State ZIP Site status
Medical & Surgical Specialists, LLC Galesburg Illinois 61401
Cancer Care Center of Southern Indiana Bloomington Indiana 47403
Elkhart Clinic Elkhart Indiana 46515
Fort Wayne Oncology & Hematology, Inc Fort Wayne Indiana 46815
Indiana University Cancer Center Indianapolis Indiana 46202
Quality Cancer Center (MCGOP) Indianapolis Indiana 46202
Community Regional Cancer Center Indianapolis Indiana 46256
Medical Consultants, P.C. Muncie Indiana 47303
Northern Indiana Cancer Research Consortium South Bend Indiana 46601
AP&S Clinic Terre Haute Indiana 47804
Center for Hematology/Oncology of S. Michigan Jackson Michigan 49201

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00216073, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 1, 2011 · Synced Apr 29, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00216073 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →